Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$44.81
-$1.20(-2.78%)
At close: 4:00 PM EDT
$44.81
-$1.20(-2.78%)
Day’s Range― - ―
52-Week Range$10.46 - $49.70
Previous CloseN/A
Volume580.10K
Average Volume (3M)2.41M
Market Cap
$4.79B
Enterprise Value$4.16B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$36.47M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 05, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.44
Shares Outstanding134,366,940
10 Day Avg. Volume2,062,066
30 Day Avg. Volume2,407,213
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.24
Forecast
1Y Price Target
$72.75Price Target Upside62.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-3.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical ValidationRepeated Phase 3 success provides meaningful clinical validation for DT120 and reduces development uncertainty versus an early-stage program. Consistent efficacy, rapid onset, and no new safety signals strengthen the potential for regulatory progress and eventual commercial differentiation.
Regulatory PositioningBreakthrough Therapy designation recognizes DT120’s potential to address a serious condition with substantial unmet need and may support more intensive FDA interaction. Combined with positive Phase 3 data, it strengthens the program’s regulatory positioning and strategic value.
Balance Sheet StrengthA sizable equity and asset base with modest absolute debt gives Definium greater financial capacity than a highly leveraged development-stage biotech. This supports continued clinical and regulatory investment while reducing near-term solvency pressure, although operating losses remain significant.
Bears Say
No Commercial RevenueThe absence of revenue confirms that Definium remains dependent on development progress rather than an operating commercial franchise. Until a candidate is approved and launched, the company has no demonstrated product-driven cash inflow to offset research, regulatory, and corporate costs.
Widening LossesMaterial deterioration in EBIT and net income indicates that the cost base is rising faster than any path to earnings, increasing the resources required to reach commercialization. Persistent and widening losses can reduce financial flexibility and make future funding needs more consequential.
Accelerating Cash BurnHigher absolute cash outflows show that Definium is consuming capital more rapidly while still generating no operating cash. Continued burn may require additional financing before products produce revenue, creating ongoing funding dependence and potential dilution risk despite the supportive balance sheet.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics’s price range in the past 12 months?
Definium Therapeutics lowest stock price was $10.46 and its highest was $49.70 in the past 12 months.
What is Definium Therapeutics’s market cap?
Definium Therapeutics’s market cap is $4.79B.
When is Definium Therapeutics’s upcoming earnings report date?
Definium Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Definium Therapeutics’s earnings last quarter?
Definium Therapeutics released its earnings results on Aug 06, 2026. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$0.541 by -$0.899.
Is Definium Therapeutics overvalued?
According to Wall Street analysts Definium Therapeutics’s price is currently Undervalued.
Does Definium Therapeutics pay dividends?
Definium Therapeutics does not currently pay dividends.
What is Definium Therapeutics’s EPS estimate?
Definium Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Definium Therapeutics have?
Definium Therapeutics has 134,366,940 shares outstanding.
What happened to Definium Therapeutics’s price movement after its last earnings report?
Definium Therapeutics reported an EPS of -$1.44 in its last earnings report, missing expectations of -$0.541. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Definium Therapeutics?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.75 (62.35% Upside)
$72.75 (62.35% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 93%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.04%
12-Months-Change
Fundamentals
Return on Equity
-85.23%
Trailing 12-Months
Asset Growth
319.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Definium Therapeutics
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
DFTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$72.75
▲(62.35% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
3.25% Insiders
7.93% Mutual Funds
0.10% Other Institutional Investors
79.05% Public Companies and Individual Investors